UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
washington, d.c. 20549
|
FORM 8-K
|
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 15, 2011
_______________________
CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)
_________________________
|
Florida
|
1-13165
|
59-2417093
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (770) 419-3355
_____________________________________________________________
(Former name or former address, if changed since last report)
_________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 7 Regulation FD
Item 7.01 Regulation FD Disclosure.
In connection with presentations that will be conducted by the management of CryoLife, Inc. (“CryoLife”) at conferences occurring on November 15, 2011 and November 16, 2011, CryoLife has posted slides (the “Slides”) to be used in conjunction with the presentations on its website at www.cryolife.com under Investor Relations, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Except for the historical information contained in the Slides, the statements made by CryoLife are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. CryoLife’s future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Slides. Forward-looking statements in the Slides are subject to certain risks and uncertainties described in the Slides, at the end thereof. For further information on other risk factors, please refer to “Risk Factors” contained in CryoLife’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the Securities and Exchange Commission, and its subsequent filings.
The Slides are being furnished, not filed, pursuant to Item 7.01 of Form 8-K. Accordingly, information contained in the Slides will not be incorporated by reference into any registration statement filed by CryoLife under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
CryoLife’s Form of 2011 Grant Agreement to Executive Officers pursuant to the CryoLife, Inc. 2007 Executive Incentive Plan entered into with each Named Executive Officer (the “2011 Grant Agreement”) is also attached hereto as Exhibit 99.2. The 2011 Grant Agreement is being filed, not furnished, under the Securities Exchange Act of 1934, as amended.
Section 9 Financial Statements and Exhibits.
Item 9.01(d) Exhibits.
(a) Financial Statements.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions.
Not applicable.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
|
99.1*
|
Slides posted at www.cryolife.com on November 15, 2011
|
|
|
99.2**
|
Form of 2011 Grant Agreement to Executive Officers pursuant to the CryoLife, Inc. 2007 Executive Incentive Plan entered into with each Named Executive Officer
|
|
|
*
|
This exhibit is furnished, not filed.
|
|
|
**
|
This exhibit is filed, not furnished.
|
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CRYOLIFE, INC. | |||
|
Date: November 15, 2011
|
By:
|
/s/ D.A. Lee | |
| Name: | D. Ashley Lee | ||
| Title: | Executive Vice President, Chief | ||
| Operating Officer and Chief | |||
| Financial Officer | |||
-3-
EXHIBIT 99.1
[PHOTO OF SCIENCE EQUIPMENT] [PHOTO OF BOY] [PHOTO OF SCIENCE EQUIPMENT]
STEVEN G. ANDERSON, PRESIDENT & CEO
[PHOTO OF SCIENCE EQUIPMENT] [PHOTO OF WOMAN AND CHILD] [PHOTO OF SURGEON]
Forward Looking Statements
Statements made in this presentation that look forward in time or that express management's beliefs, expectations, hopes or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties, including those detailed in CryoLife’s Form 10-K filing for the year ended December 31, 2010, and later SEC filings as well as on the last slide of this presentation. The Company does not undertake to update its forward-looking statements.
2
CryoLife Investment Highlights
|
Focused Business Model
|
• Products and technology addressing complex cardiac and vascular surgery
|
|
Diversified Product Portfolio
|
• Leading market share positions addressing $1B + total opportunity in various cardiovascular product segments
|
|
Specialized Sales Force
|
• ~70 person sales team; deep relationships with cardiac and vascular surgeons; distributors in 70 + countries
|
|
World Class Training Programs
|
• 200+ physicians trained per year at in-house facility and off-site workshops
|
|
Executing Strategic Acquisitions
|
• Cardiovascular companies with innovative technology
|
|
Robust Product Pipeline
|
• U.S. approval for PerClot & BioFoam could expand total addressable market by $1.5B in 2015
|
3
Market Leading Product Platforms
GRAPHIC SHOWING THE FOLLOWING:
|
•
|
Tissue Processing
|
|
•
|
Cardiac Allograft Tissue
|
|
•
|
Vascular Allograft Tissue
|
|
•
|
Medical Devices
|
|
•
|
Cardiogenesis
|
|
•
|
Investment in ValveXchange
|
|
•
|
Surgical Sealants & Hemostats
|
|
•
|
PerClot
|
|
•
|
BioGlue
|
|
•
|
BioFoam
|
4
Strategic Growth Objectives
Drive Revenue Growth – Expand Gross Margins – Improve Profitability
|
Acquisitive Growth
|
• Acquire innovative products and technologies to accelerate top line
• Focus on cardiac and vascular surgery
• Target deals that have a clear path to shareholder value
• Integrate products into global sales force
• Leverage commercial and clinical infrastructure
|
|
Organic Growth
|
• Commercialize innovative new products in core markets
• Invest strong cash flow into R&D and clinical trials
• Build leadership positions in base business
|
5
Recent Business Developments
|
•
|
Starch Medical – September, 2010
|
|
–
|
Worldwide distribution and manufacturing agreement for PerClot®, a novel second-generation hemostatic agent used in surgery
|
|
•
|
BioGlue Japan Launch – April, 2011
|
|
–
|
Provided entry into second largest worldwide market for surgical hemostats and sealants
|
|
•
|
Cardiogenesis – May, 2011
|
|
–
|
Accretive acquisition (excluding acquisition and integration costs), provided entry into Transmyocardial Revascularization (TMR) market with high margin medical device
|
|
•
|
ValveXchange – July, 2011
|
|
–
|
Lifetime heart valve replacement technology platform spun-off from Cleveland Clinic
|
|
–
|
19% initial equity ownership and right of first refusal to acquire Company
|
6
Diversified and Growing Market Opportunities
PIE CHARTS SHOWING THE FOLLOWING:
Total Addressable Market
$ in Millions
2011
|
BioGlue
|
$464
|
|
CardioGenesis
|
$175
|
|
BioFoam EU
|
$30
|
|
PerClot EU
|
$328
|
|
Allograft Cardiac Tissue
|
$50
|
|
Allograft Vascular Tissue
|
$68
|
2015
|
BioGlue
|
$698
|
|
CardioGenesis
|
$182
|
|
BioFoam EU
|
$34
|
|
PerClot EU
|
$468
|
|
Allograft Cardiac Tissue
|
$56
|
|
Allograft Vascular Tissue
|
$84
|
7
Focused Sales and Distribution
|
•
|
~70 (50 U.S.) person direct sales team poised to further penetrate cardiac and vascular surgeon market
|
|
•
|
Relationships with over 1,000 cardiac and vascular surgeons
|
|
•
|
Independent distributors covering 70+ countries
|
|
•
|
Leading annual cardiovascular surgeon training event (Ross Summit) draws significant attendance
|
[PHOTO OF SURGEONS]
8
BioGlue® & BioFoam® Protein Hydrogel Technologies
|
|
BioGlue
|
|
•
|
Dominant adhesive/sealant for cardiovascular
|
|
|
surgery; over 650,000 procedures worldwide
|
|
•
|
Overcomes air and fluid leakage challenges with
|
|
|
sutures and staples
|
|
•
|
4-5x tensile strength of fibrin sealants
|
|
•
|
U.S., European and Shonin (Japanese) approval
|
|
|
BioFoam
|
|
•
|
Surgical adhesive biogel expands 4-5x and quickly solidifies into soft foam
|
|
•
|
Stored at room temperature
|
|
•
|
CE Mark for parenchymal organ sealing; EU launch April 2010
|
|
•
|
Commencing US clinical trials; projected U.S. approval 2015/16
|
[PHOTO OF SCIENCE EQUIPMENT]
9
PerClot® - Significant Growth Opportunity
|
•
|
Next generation hemostatic agent derived from plant starch; rapid blood absorption
|
|
•
|
$1.3 Billion worldwide market growing to ~$1.9 billion in 2015
|
|
•
|
Decreases disease transmission and immunologic response; no human or animal components
|
|
•
|
Ready-to-use at surgical site
|
|
–
|
No pre mixing or carrier use
|
|
–
|
Room temperature storage
|
|
•
|
Worldwide distribution & technology licensing agreement
|
|
•
|
CE Mark; international distribution began 4Q 2010; U.S. approval expected no later than 2014
|
[PHOTO OF MEDICAL PROCEDURE]
[PHOTO OF SCIENCE EQUIPMENT]
10
Cardiac Allograft Tissue
|
•
|
Dominant player with >50% market share
|
|
•
|
Ideal for young women and children
|
|
•
|
Lower rate of calcification vs. animal tissues
|
|
•
|
No need for blood thinners vs. mechanical valves
|
|
•
|
No synthetic materials vs. porcine/bovine valves
|
|
•
|
Broad product offering for cardiac reconstruction
|
|
–
|
Preserved human valves
|
|
–
|
CryoValve SG Pulmonary Human Heart Valve
|
|
–
|
CryoPatch material for cardiac reconstruction
|
[PHOTO OF TISSUE]
[PHOTO OF TISSUE]
[PHOTO OF MEDICAL PROCEDURE]
11
Vascular Allograft Tissue
|
•
|
Vascular disease is a significant co-morbidity of diabetes
|
|
•
|
Broad product offering
|
|
–
|
Saphenous veins, femoral veins & arteries, aortoiliac grafts
|
|
–
|
Used in limb salvage due to vascular disease, aortoiliac replacements, dialysis access, cardiac bypass
|
|
•
|
Overcomes poor performance of synthetic grafts below-the-knee
|
|
–
|
Graft kinking and occlusion
|
|
–
|
Infection complications
|
[PHOTO OF TISSUE]
[PHOTO OF SCIENCE EQUIPMENT]
[PHOTO OF TISSUE]
12
Transmyocardial Revascularization (TMR)
|
•
|
Treatment for no-option patients with severe angina, incomplete revascularization and chronic ischemic heart disease
|
|
•
|
Proprietary intramyocardial catheters
|
|
•
|
Intraoperative procedure performed by cardiac surgeon
|
|
•
|
Epicardial nature of procedure allows for direct vision of surgical area
|
|
•
|
Produces transmural channels of 1mm in diameter
|
|
•
|
Medicare approved and reimbursable
|
[PHOTO OF PROCEDURE]
TMR
[PHOTO OF HUMAN BODY]
13
Cardiogenesis Acquisition
|
Increases Addressable Market Opportunity
|
• Adds $175 million initially, and up to $700 million with biologics
|
|
Expanded Portfolio Allows For Significant Growth
|
• 2010 revenue of $11.3M with >80% gross margin
|
|
Strong Anticipated ROI
|
• Expected break even within first year (excluding transaction and integration related charges and costs)
|
Cardiogenesis Products
|
[Photo of Sologrip® III Mini-thoracotomy]
|
[Photo of Surgery]
[Photo of PEARL™ 5.0 Robotic Delivery]
|
[Photo of Solargen™ 2100s Laser Console]
|
|
Sologrip® III Mini-thoracotomy
|
PEARL™ 5.0 Robotic Delivery
|
Solargen™ 2100s Laser Console
|
14
Next Generation Phoenix Intramyocardial Delivery System
|
•
|
Innovative Revascularization approach utilizing autogenous stem cell biologics to increase angiogenesis
|
|
•
|
CE Mark Approval; Planning 30 patient European study to commence in 2012
|
|
•
|
U.S. clinical trials expected to commence in 2012
|
Phoenix Procedure
|
[Photo of Laser fiber deployed]
Laser fiber deployed 1
|
[Photo of Three needles with side holes deployed]
Three needles with side holes deployed 2
|
[Photo of 1 cc stem cells injected]
1 cc stem cells injected 3
|
[Photo of Stem cells injected into the laser border zone]
Stem cells injected into the laser border zone 4
|
15
ValveXchange: Investing in Complementary Heart Valve Technology
Vanguard™ Transapical
[PHOTO OF MEDICAL TECHNOLOGY]
|
•
|
Next-generation lifetime heart valve replacement technology
|
|
–
|
Features potential transapical leaflet replacement; potentially overcomes long-term leaflet wear, which currently requires invasive replacement surgery
|
|
–
|
Applicable to patients of all ages
|
|
•
|
$1.5+ billion worldwide heart valve market, including rapidly expanding TAVI market
|
|
•
|
19% initial equity ownership with right of first refusal for acquisition
|
|
–
|
$3.5 million investment; $2.0 million revolving credit facility
|
16
Leveraging Core Business to Invest in Growth Opportunities
TIMELINE GRAPHIC SHOWING THE FOLLOWING:
BioFoam CE Mark
2010
Perclot WW distribution and manufacturing agreement with Starch Medical
BioGlue Japan Approval
Perclot EU Launch
2011
BioGlue Japan Launch
Cardiogenesis Acquisition
ValveXchange Equity Investment
BioFoam US IDE Feasibility Study
2012
Cardiogenesis Integration Complete
CryoValve SG Aortic Valve Launch
Cardiogenesis Initiate 30 Patient European Phoenix Stem Cell Study
2013
2014
Perclot US Launch
2015
BioFoam US Launch
17
Growing Annual Revenues ($ in millions)
BAR CHART SHOWING THE FOLLOWING:
|
2006
|
$81.3
|
|
2007
|
$94.8
|
|
2008
|
$105.0
|
|
2009
|
$111.7
|
|
2010
|
$116.6
|
|
2011E
|
$121.0
|
|
2012E
|
$130.0
|
|
2013E
|
$140.0
|
18
Strong Cash & Cash Equivalents ($ in millions)
BAR CHART SHOWING THE FOLLOWING:
|
2007
|
$17.5
|
|
2008
|
$22.8
|
|
2009
|
$35.1
|
|
2010
|
$40.8
|
|
9/30/2011
|
$26.0*
|
|
Investments over past 2 years (prior to 9/30/2011)
|
|
|
PerClot Technology Acquisition
|
$6.75 million
|
|
Cardiogenesis Acquisition
|
$21.7 million
|
|
Investment in ValveXchange
|
$3.5 million
|
|
Stock Buyback Program
|
$7.3 million
|
|
Business Development
|
$5.1 million
|
|
Total
|
$44.35 million
|
* Includes $5.3M in restricted cash
19
Expanding Pipeline Drives Market Opportunity
Total Addressable Worldwide Market
PIE CHARTS SHOWING THE FOLLOWING:
2011: $1.1B
|
Current Products
|
$1.1B
|
2015: $3.5B
|
Current Products
|
$1.5B
|
|
PerClot Worldwide
|
$1.4B
|
|
BioFoam US
|
$77
|
|
CardioGenesis (Phoenix)
|
$518
|
Current Products : BioGlue, Cardiogenesis, Biofoam EU, Perclot EU, Allograft cardiac/vascular tissue
Perclot Worldwide : Excludes EU
20
CryoLife.com
21
FORWARD LOOKING STATEMENT
Statements made in this presentation that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These statements include those regarding the estimated dollar value of the total opportunity in various cardiovascular product segments, the number of physicians trained annually at our in-house facility and off-site workshops, estimates regarding CryoLife’s total addressable market and the addressable market for each of its products and services, and potential growth of CryoLife’s total addressable market and the addressable market for each of its products and services by 2015, the potential for U.S. approval of PerClot and BioFoam to expand CryoLife’s total addressable market by $1.5 billion by 2015, the anticipated timing of U.S. approval for PerClot and BioFoam, growth estimates for the worldwide market for PerClot, plans regarding strategic growth objectives and the potential benefits of these growth objectives, including revenue growth, expansion of gross margins and improved profitability, plans to invest strong cash flow into R&D and clinical trials, the ability of CryoLife’s direct sales team to further penetrate the cardiac and vascular surgeon market, expected benefits of the Cardiogenesis acquisition, expectations regarding the addressable worldwide market for the Cardiogenesis Phoenix Intramyocardial Delivery System in 2015, anticipated timing of a European study and U.S. clinical trials for the next generation Phoenix Intramyocardial Delivery System, expectations regarding the worldwide heart valve market and the TAVI market, the long-term benefits of ValveXchange’s heart valve replacement technology, expected timing for the launch of various products and related regulatory approvals, and annual revenue projections for CryoLife. Those risks and uncertainties that could cause the events addressed in these forward-looking statements not to occur as expected include that estimates regarding the worldwide addressable market for various products and services, as well as all of CryoLife’s products and services in the aggregate, may not be correct and could be impacted by regulatory issues, the introduction of competing products and services into the market, the changing preferences and needs of patients and their physicians, and the ability of CryoLife to successfully market and distribute its products and services in multiple countries and jurisdictions. Investors should be particularly cautious with respect to projections beyond fiscal 2012, as longer-term estimates are more difficult to forecast with accuracy and general economic conditions and the market for CryoLife’s products and services may change substantially. The number of physicians trained annually at CryoLife’s in-house facility and off-site workshops may change and past attendance at these training sessions may not be indicative of future attendance. Also, there may not be a strong future correlation between current relationships with physicians and attendance at CryoLife-sponsored workshops and revenue ultimately generated by CryoLife products and services. Estimates regarding the timing of regulatory approvals for CryoLife products are subject to factors beyond CryoLife’s control and CryoLife may not be able to obtain the necessary approvals in a timely or cost-efficient manner, if at all. Plans regarding CryoLife’s strategic growth objectives and its use of cash are subject to change based on the various business needs of the Company. Management may choose to allocate its assets in ways that are currently unanticipated and there is no guarantee that CryoLife will continue to pursue strategic acquisitions or invest in R&D and clinical trials. Current plans with respect to growth opportunities are subject to change, and management may ultimately determine that there are better uses for our cash based on numerous factors.
22
FORWARD LOOKING STATEMENT - continued
|
Any business development efforts and/or R&D investments are subject to delays, cost overages and regulatory difficulties, and efforts to fully integrate future acquisitions and new product offerings into our business, or efforts relating to R&D and clinical trials, may not be successful and can potentially disrupt our normal business activities. CryoLife’s projections regarding annual revenues may be materially impacted by CryoLife’s ability to obtain certain regulatory approvals on a timely basis, its ability to successfully market various products and services in multiple countries and jurisdictions, and changing economic conditions generally. CryoLife has also inherited certain risks and uncertainties related to its recent acquisition of Cardiogenesis' business. These risks and uncertainties include that CryoLife's ability to maintain revenues and achieve growth in revenues from Cardiogenesis’ revascularization technology in the future is dependent upon physician awareness of this technology as a safe, efficacious, and appropriate treatment for their patients, CryoLife may not be able to successfully market Cardiogenesis' revascularization technology if third party reimbursement for the procedures performed with this technology is not available for its health care provider customers, if suppliers or manufacturers with respect to Cardiogenesis products fail to comply with ongoing FDA or other foreign regulatory authority requirements, CryoLife's Cardiogenesis business may be negatively impacted, third-party distributors or CryoLife's own distributors may not effectively distribute Cardiogenesis products, CryoLife's international operations with respect to Cardiogenesis subject it to certain operating risks, which could adversely impact its net sales, results of operations and financial condition, Cardiogenesis has been named as a defendant in a patent infringement lawsuit and costly litigation may be necessary to protect or defend its intellectual property rights, and Cardiogenesis' internal controls over financial reporting may not have been effective prior to the merger, which could have a significant and adverse effect on CryoLife. These risks and uncertainties related to Cardiogenesis' business that CryoLife has inherited also include the risk factors detailed in Cardiogenesis' Securities and Exchange Commission filings, including its Form 10-K filing for the year ended December 31, 2010, and Cardiogenesis' other SEC filings. Our anticipated future performance, including revenue projections, is subject to the general risks associated with our business, including that we are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product, including that a German Patent Court has nullified our main BioGlue patent in Germany, and if the ruling is upheld on appeal, we would be prevented from suing to prevent third parties from infringing the main BioGlue patent in Germany, the integration of Cardiogenesis’ business into our business may be slower than expected or unsuccessful, and our revenues and operating expenses may be materially adversely impacted as a result, we are subject to stringent domestic and foreign regulation which may impede the approval process of our tissues and products, hinder our development activities and manufacturing processes, and, in some cases, result in the recall or seizure of previously cleared or approved tissues and products, our liquidity and earnings may be impacted by our substantial investment in our distribution and license and manufacturing agreements with SMI, and we may not fully realize the benefit of our investment in future years unless we are able to obtain FDA approval for PerClot in the U.S., which will require an additional commitment of funds, the FDA rejected our initial IDE application for PerClot and we are working to address its concerns, but there is no guarantee that we can do so on a timely or cost efficient basis, if at all, uncertainties related to patents and protection of proprietary technology may adversely affect the value of our intellectual property, we are involved in significant litigation with Medafor and that litigation cost may have a material adverse impact on our profitability
|
23
FORWARD LOOKING STATEMENT - continued
Medafor has filed counter-claims against us with respect to our lawsuit against Medafor, and if Medafor is successful in its claims, our revenues and profitability may be materially, adversely impacted, we may be unsuccessful in our efforts to market and sell PerClot in the U.S. and internationally, our investment in Medafor may have been impaired due to Medafor’s termination of our distribution agreement with Medafor, which could have a material adverse impact on our financial condition and profitability, the tissues we process and our products allegedly have caused and may in the future cause injury to patients, and we have been and may be exposed to product liability claims, including one currently outstanding product liability lawsuit, and additional regulatory scrutiny as a result, we may expand through acquisitions or licenses of or investments in other companies or technologies, which may result in additional dilution to our stockholders and consume resources that may be necessary to sustain our business, we may find it difficult to integrate recent acquisitions of technology and potential future acquisitions of technology or business combinations, which could disrupt our business, dilute stockholder value, and adversely impact our operating results, we may not realize the anticipated benefits from an acquisition and could acquire unforeseen liabilities in connection with acquisitions, demand for our tissues and products could decrease in the future, which could have a material adverse effect on our business, the success of many of our tissues and products depends upon strong relationships with physicians, consolidation in the health care industry could lead to demands for price concessions, limits on the use of our tissues and products, or eliminate our ability to sell to certain of our significant market segments, healthcare policy changes, including recent federal legislation to reform the U.S. healthcare system, may have a material adverse effect on us, our existing insurance policies may not be sufficient to cover our actual claims liability, we are dependent on the availability of sufficient quantities of tissue from human donors, our CryoValve SGPV post-clearance study may not provide expected results, intense competition may affect our ability to operate profitably, the loss of any of our sole-source suppliers could have an adverse effect on our revenues, financial condition, profitability, and cash flows, regulatory action outside of the U.S. has affected our business in the past and may affect our business in the future, rapid technological change could cause our services and products to become obsolete, continued fluctuation of foreign currencies relative to the U.S. Dollar could materially and adversely impact our business, our credit facility limits our ability to pursue significant acquisitions, key growth strategies may not generate the anticipated benefits, our ability to borrow under our credit facility may be limited, we may not be able to enter into a new credit facility after our current credit facility expires, we may not be successful in obtaining necessary clinical results and regulatory approvals for services and products in development, and our new services and products may not achieve market acceptance, investments in new technologies and acquisitions of products or distribution rights may not be successful, extensive government regulation may adversely affect our ability to develop and market services and products, if we are not successful in expanding our business activities in international markets, we may be unable to increase our revenues, we are not insured against all potential losses, and natural disasters or other catastrophes could adversely affect our business, financial condition and profitability, we may be unable to obtain adequate insurance at a reasonable cost, if at all, and we are dependent on key personnel. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2010, and subsequent SEC filings. CryoLife does not undertake to update its forward-looking statements.
24
EXHIBIT 99.2
AMENDED AND RESTATED
FISCAL YEAR ____
BONUS AGREEMENT
UNDER THE
2007 EXECUTIVE INCENTIVE PLAN
This AMENDED AND RESTATED CRYOLIFE, INC. FISCAL YEAR ____ EXECUTIVE INCENTIVE PLAN BONUS AGREEMENT (this “Agreement”) was adopted by the Plan Committee pursuant to the CryoLife, Inc. (the “Company”) 2007 Executive Incentive Plan (the “Plan”) (a copy of which is attached as Exhibit 1) and agreed to by the Company and ________ (“Executive”) effective _______ __, ____. This Agreement is effective for the fiscal year ending December 31, ____ (the “Plan Year”). Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Plan.
1. Calculation of Bonus. Subject to the further adjustments, limitations and additions provided for in the Plan and this Agreement, Executive’s bonus for the ____ fiscal year shall be computed as set forth on Exhibit 2 attached hereto.
2. Term of Agreement. This Agreement shall be effective only for the Plan Year (i.e., the fiscal year ending December 31, ____).
3. No Employment Arrangement Implied. Nothing in this Agreement or the Plan shall imply any right of Employment for Executive, and except as set forth in Section 10 of the Plan with respect to a Change of Control or as otherwise determined by the Committee, in its discretion, or contained in any other agreement between Executive and the Company, which shall not be affected hereby, if Executive is terminated, voluntarily or involuntarily, with or without cause, prior to the end of the Plan Year, Executive shall not be entitled to any bonus for the Plan Year regardless of whether or not such bonus had been or would have been earned in whole or in part, but any unpaid bonus earned with respect to a prior fiscal year shall not be affected.
4. Plan Provisions shall Govern. This Agreement is subject to and governed by the Plan and in the case of any conflict between the terms of this Agreement and the contents of the Plan, the terms of the Plan will control.
5. Governing Law. The interpretation, construction and performance of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Georgia without regard to the principle of conflict of laws.
6. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.
7. Severability. Provided the other provisions of this Agreement do not frustrate the purpose and intent of the law, in the event that any portion of this Agreement shall be determined to be invalid or unenforceable to any extent, the same shall to that extent be deemed severable from this Agreement, and the invalidity or unenforceability thereof shall not affect the validity and enforceability of the remaining portion of this Agreement.
8. Amendment and Termination. The Company may amend this Agreement, at any time prior to the payment of the bonus, without the approval of Executive. Notwithstanding anything to the contrary contained in this Agreement, the Company may terminate this Agreement at any time prior to the payment of the bonus and Executive shall not be entitled to any bonus under this Agreement for the Plan Year regardless of when this Agreement is terminated.
1
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by a duly authorized officer of the Company and Executive has executed this Agreement as of the day and year first written above.
|
CRYOLIFE, INC.
|
EXECUTIVE
|
|
By: ___________________________
|
___________________________
|
|
Title: _________________________
|
2
EXHIBIT 1
“PLAN”
3
EXHIBIT 2
_____________________
Executive may earn an additional percentage of Executive’s base salary based on three components: (i) the Company attaining specified adjusted revenue targets; (ii) the Company attaining specified adjusted net income targets and (iii) the Executive’s personal performance review. Executive’s target bonus of __% is based on the achievement of __% of target in each of the three components (__% for Adjusted Revenues, __% for Adjusted Net Income, __% for Personal Performance).
No bonus is payable in a given category if the specified minimum set forth below in that category is not obtained. Subject to the provisions of the Plan and the discretion of the Committee, all bonuses will be paid in cash. Details regarding bonus calculation are set forth below, with the __% target level bolded for ease of reference (data points shown in the tables, other than the minimum and maximum levels, are representative only, and a pro rata portion of the bonus shall be earned for performance achieved that falls between the data points shown):
|
Adjusted Revenues*
|
|||||||||||
|
Adjusted Revenue*
Target
(in thousands)
|
$_____
Minimum
Level
|
$______
|
$______
|
$______
|
$______
|
$______
|
$_____
|
$_____
|
$______
|
$______
|
$______
|
|
Bonus Payable
|
$______
|
$______
|
$_______
|
$_______
|
$________
|
$________
|
$________
|
$_______
|
$_______
|
$_______
|
$_______
|
* Adjusted Revenues are fiscal ____ Company revenues from (i) cardiac and vascular allograft tissue processing, (ii) BioGlue, BioFoam and related product sales, (iii) PerClot sales and (iv) Cardiogenesis sales.
** There is no maximum level for adjusted revenues. Achievement of adjusted revenues above this level will result in bonus payments on a sliding scale consistent with the above payment ratios.
4
|
Adjusted Net Income*
|
|||||||||||
|
Adjusted Net Income* Target (in thousands)
|
$______
Minimum
Level
|
$______
|
$______
|
$______
|
$______
|
$______
|
$_______
|
$______
|
$______
|
$______
|
$______
|
|
Bonus Payable
|
$______
|
$________
|
$_______
|
$_______
|
$_______
|
$_______
|
$_______
|
$________
|
$_______
|
$______
|
$_______
|
* Adjusted Net Income is GAAP net income for ____, exclusive of interest expense, interest income, stock compensation expense (other than stock compensation expense related to the bonus plan), R&D expense (excluding salaries and related expenses), other income and expense, income taxes, grant revenue, charges related to acquisitions/license/business development/integration, and litigation costs.
** There is no maximum level for adjusted net income. Achievement of adjusted net income above this level will result in bonus payments on a sliding scale consistent with the above payment ratios.
|
Personal Performance
|
||
|
Personal Performance Rating
|
Does Not
Meet
|
Meets or
Exceeds
|
|
Bonus Payable
|
$____
|
$________
|
5